Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential R-FC and Zevalin in Relapsed NHL
NCT00397800Phase 2Unknown
- Sponsor
- Technical University of Munich
- Start
- Jun 2005
- Primary completion
- May 2008
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in B-cell non-Hodgkin lymphoma, sponsored by Technical University of Munich. Primary endpoints: Dose-Limiting Toxicity and Maximum Tolerated Dose. Status: unknown.
02
Drugs
ibritumomab tiuxetan
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00397800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00397800.